Loading…
Evommune, Inc. is projected to rise to $11.54 by 2027, a +3% move from its current price of $11.25. EVMN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $10.80 | $11.25 | $11.73 | +0.03% |
| Aug 4 | $10.62 | $11.26 | $11.93 | +0.06% |
| Aug 5 | $10.48 | $11.26 | $12.10 | +0.10% |
| Aug 6 | $10.37 | $11.26 | $12.23 | +0.13% |
| Aug 7 | $10.27 | $11.27 | $12.36 | +0.16% |
| Aug 8 | $10.19 | $11.27 | $12.47 | +0.19% |
| Aug 9 | $10.11 | $11.28 | $12.58 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.11 | $11.28 | $12.58 | +0.23% |
| Week 2 | $9.68 | $11.30 | $13.19 | +0.46% |
| Week 3 | $9.37 | $11.33 | $13.69 | +0.68% |
| Week 4 | $9.12 | $11.35 | $14.12 | +0.91% |
| Week 5 | $8.91 | $11.38 | $14.53 | +1.14% |
| Week 6 | $8.73 | $11.40 | $14.90 | +1.37% |
| Week 7 | $8.56 | $11.43 | $15.26 | +1.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Evommune, Inc. is a clinical-stage biotechnology company operating in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC.
The company was incorporated in 2020 and is headquartered in Palo Alto, California. It operates in the Healthcare sector.
Evommune, Inc. trades on the public markets as EVMN. The current price is $11.71 and the market cap is $421.78M. It is ranked 3124.
The near-term price outlook is bearish, with RSI(14) at 30. The stock is trading near support at $11.71 and faces resistance at $25.18.
The 30-day range runs from $8.31 to $16.50, and the stock shows high volatility at 100% annualized. The 50-day simple moving average stands at $19.76, and the current price remains below this level.
Forecast highlights show a path from a flat start in 2026 to notable gains later, with 2030 averaging $17.03 and a projected max of $34.05 (ROI 45.4%), and 2050 averaging $45.79 with a max of $105.31 (ROI 291%).
A major floor 84.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.8% away) — a key level to hold.
The nearest ceiling, 123.8% above — a clean break opens room to run.
A major ceiling 166.3% above — clearing it would confirm fresh momentum.
Key EVMN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EVMN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.27 | Sell | $11.30 | Sell |
| MA 10 | $11.42 | Sell | $11.57 | Sell |
| MA 20 | $12.01 | Sell | $12.72 | Sell |
| MA 50 | $17.26 | Sell | $16.11 | Sell |
| MA 100 | $20.77 | Sell | $18.70 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.87 | Neutral |
| Stoch RSI (14) | 78.02 | Neutral |
| CCI (20) | -78.70 | Neutral |
| Williams %R (14) | -85.71 | Info |
| MACD (12,26,9) | 0.27 | Buy |
| ROC (12) | -9.64 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 14.29 | Buy |
| TRIX (15) | -1.89 | Sell |
| Awesome (5,34) | -3.93 | Sell |
| Ultimate (7,14,28) | 40.19 | Neutral |
| Momentum (10) | -0.89 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 11.15 | Buy |
| ADX (14) | 32.34 | Sell |
| ATR (14) | 0.57 | Info |
The 30-day technical picture is bearish, with sentiment labeled BEARISH and RSI(14) at 30. The current price of $11.71 sits near the $11.71 support and beneath the $19.76 50-day SMA.
The 30-day range spans $8.31 to $16.50, with resistance at $25.18.
This setup suggests limited near-term upside unless buyers push the price above the $19.76 level or beyond the $25.18 resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.05 | $11.25 | $15.40 | 0% | Neutral | |
| $8.15 | $11.54 | $17.72 | +3% | Neutral | |
| $7.39 | $11.28 | $18.62 | 0% | Neutral | |
| $9.26 | $15.06 | $26.25 | +34% | Bullish | |
| $9.36 | $16.13 | $29.41 | +43% | Bullish | |
| $8.04 | $14.65 | $27.76 | +30% | Bullish | |
| $7.68 | $14.77 | $28.94 | +31% | Bullish | |
| $6.93 | $14.03 | $28.32 | +25% | Bullish | |
| $7.12 | $15.18 | $31.50 | +35% | Bullish | |
| $8.51 | $18.90 | $40.23 | +68% | Bullish | |
| $8.87 | $19.71 | $45.33 | +75% | Bullish | |
| $19.68 | $43.72 | $100.56 | +289% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $11.05 | $11.25 | $13.85 | +0.00% |
| September 2026 | $9.43 | $11.58 | $14.92 | +2.97% |
| October 2026 | $9.28 | $11.59 | $15.26 | +0.03% |
| November 2026 | $8.81 | $11.14 | $14.94 | -3.89% |
| December 2026 | $8.82 | $11.29 | $15.40 | +1.42% |
Click any year to see its month-by-month EVMN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Evommune, Inc.'s 2026 outlook centres on $11.25, within a $11.05 to $15.40 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, EVMN could reach as high as $17.72, with a base case around $11.54 and support toward $8.15 — roughly +3% from $11.25. Price action looks broadly range-bound.
Expect EVMN to range from $7.39 to $18.62 through 2028. The $11.28 average target implies a 0% move from current prices. That is -2% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The EVMN price prediction for 2029 points to an average of $15.06 (low $9.26, high $26.25) — a potential gain of +34% on today's $11.25. Momentum favours further upside here.
In 2030, EVMN is projected to trade between $9.36 and $29.41, averaging $16.13 — a potential gain of +43% from today's $11.25. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Evommune, Inc.'s 2031 outlook centres on $14.65, within a $8.04 to $27.76 range. That is -9% versus the projected 2030 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2032, EVMN could reach as high as $28.94, with a base case around $14.77 and support toward $7.68 — roughly +31% from $11.25. Buyers look set to stay in control over this stretch.
Expect EVMN to range from $6.93 to $28.32 through 2033. The $14.03 average target implies a +25% move from current prices. That is -5% versus the projected 2032 average. Momentum favours further upside here.
The EVMN price prediction for 2034 points to an average of $15.18 (low $7.12, high $31.50) — a potential gain of +35% on today's $11.25. Buyers look set to stay in control over this stretch.
In 2035, EVMN is projected to trade between $8.51 and $40.23, averaging $18.90 — a potential gain of +68% from today's $11.25. That is up +25% on the projected 2034 average. Momentum favours further upside here.
Evommune, Inc.'s 2040 outlook centres on $19.71, within a $8.87 to $45.33 range. That is up +4% on the projected 2035 average. That marks a +75% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, EVMN could reach as high as $100.56, with a base case around $43.72 and support toward $19.68 — roughly +289% from $11.25. Momentum favours further upside here.
Investing $1,000 in EVMN today (≈ 88.888889 EVMN) could be worth
$3,886.54
+$2,886.54 (+289%) by 2050 · US Dollar
Based on the average projected EVMN price of $43.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EVMNwould be worth at today's price.
$1,000 invested in EVMN on Nov 6, 2025 (≈ 49.431538 EVMN) would be worth
$556.1
-$443.9 (-44.4%) today · 0.56× · US Dollar
Based on a EVMN entry price of $20.23 vs. today's $11.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.36 | $990.32 | -1.0% |
| 1 month ago | $12.82 | $877.54 | -12.2% |
| 3 months ago | $24.5 | $459.18 | -54.1% |
| 6 months ago | $19.23 | $585.02 | -41.5% |
| All time ago | $20.23 | $556.1 | -44.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EVMN forecast.
Our base-case forecast reaches $23.00 around 2050.
Implied market cap at $23.00: $828.42M
In the multi-year forecast, Evommune shows a gradual lift in the average price from $11.71 in 2026 to $17.03 by 2030 (ROI 45.4%) and $19.08 by 2040 (ROI 62.9%), before reaching a forecast average of $45.79 in 2050 (ROI 291%). The 2026 forecast is $11.71 (avg) with ROI 0, followed by years with mixed sentiment, including NEUTRAL in 2026–2028 and BULLISH in 2029 onward. The forecast includes 2030 avg $17.03 (ROI 45.4%), 2040 avg $19.08 (ROI 62.9%), and 2050 avg $45.79 (ROI 291%), with a max of $34.05 in 2030 and $105.31 in 2050.
Overall, the outlook shows potential upside over the longer term but with notable volatility and uncertainty, especially in the near term. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $17.03; min $8.56; max $34.05; ROI 45.4%; sentiment BULLISH.
The forecast includes years with neutral or bearish readings (e.g., 2026 avg $11.71 ROI 0; 2027 avg $11.47 ROI -2.1; 2028 avg $11.12 ROI -5) and later bullish years (e.g., 2029 avg $16.46 ROI 40.6; 2030 avg $17.03 ROI 45.4%). These are estimates, not guarantees.
The 2050 max forecast is $105.31, so reaching $100 is within the maximum scenario.
Avg $19.08; min $8.58; max $43.87; ROI 62.9%; sentiment BULLISH.
Evommune, Inc. Community Discussion
0Share your Evommune, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.